Myles Wolf

List of Publications by Year in Descending Order

244 papers	22,233 citations	68 h-index	147 g-index
270 ext. papers	25,372 ext. citations	8.5 avg, IF	6.76 L-index

#	Paper	IF	Citations
244	Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial.. *Kidney360*, **2022**, 3, 258-268	1.8	0
243	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. *Bone*, **2022**, 154, 116202	4.7	4
242	A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan.. *American Journal of Nephrology*, **2022**, 1-14	4.6	0
241	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *American Heart Journal*, **2021**, 245, 10-10	4.9	1
240	Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2021**, 36, 2282-2289	4.3	2
239	Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. *Advances in Therapy*, **2021**, 38, 3531-3549	4.1	7
238	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. *Kidney International Supplements*, **2021**, 11, e66-e76	6.3	0
237	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. *American Journal of Kidney Diseases*, **2021**, 77, 920-930.e1	7.4	7
236	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney International*, **2021**, 99, 1280-1295	9.9	18
235	Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases*, **2021**, 77, 907-919	7.4	5
234	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. *Kidney International*, **2021**, 100, 1292-1302	9.9	1
233	Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. *Nephrology Dialysis Transplantation*, **2021**, 36, 111-120	4.3	35
232	Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. *American Journal of Hematology*, **2021**, 96, E11-E15	7.1	6
231	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. *Journal of Cardiac Failure*, **2021**, 27, 309-317	3.3	2
230	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. *British Journal of Clinical Pharmacology*, **2021**, 87, 2256-2273	3.8	21
229	Mineral bone disease in autosomal dominant polycystic kidney disease. *Kidney International*, **2021**, 99, 977-985	9.9	4
228	Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. *Bone Research*, **2021**, 9, 35	13.3	3

227	Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults. *Journal of the American Heart Association*, **2021**, 10, e020196	6	3
226	Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload. *American Journal of Cardiology*, **2021**, 159, 113-120	3	
225	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. *New England Journal of Medicine*, **2021**, 385, 1750-1760	59.2	23
224	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases*, **2021**, 77, 56-73.e1	7.4	11
223	Echocardiography to Screen for Pulmonary Hypertension in CKD. *Kidney International Reports*, **2020** , 5, 2275-2283	4.1	1
222	Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 776-783	6.9	12
221	Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease. *American Journal of Epidemiology*, **2020**, 189, 433-444	3.8	3
220	Anemia and Incident End-Stage Kidney Disease. *Kidney360*, **2020**, 1, 623-630	1.8	4
219	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 1477-1488	1.2	3
218	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. *Kidney360*, **2020**, 1, 648-656	1.8	0
217	Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis. *British Journal of Pharmacology*, **2020**, 177, 4400-4415	8.6	10
216	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 1836-1846	12.7	7
215	Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 2184-2192	12.7	3
214	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study. *PLoS ONE*, **2020**, 15, e0226509	3.7	10
213	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. *JAMA - Journal of the American Medical Association*, **2020**, 323, 432-443	27.4	73
212	Health Outcomes With Vitamin D Supplementation-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 323, 1619	27.4	
211	Targeting Vascular Calcification in Chronic Kidney Disease. *JACC Basic To Translational Science*, **2020**, 5, 398-412	8.7	35
210	Kidney to bone via bedside to bench□nd back?. *Journal of Clinical Investigation*, **2020**, 130, 1106-1108	15.9	1

209	Persistent Hypophosphatemia after Ferric Carboxymaltose Is Associated with Persistent Changes in Biomarkers of Bone Metabolism. *Blood*, **2020**, 136, 13-14	2.2	1
208	The Nephrology Immersion Classroom for Internal Medicine Residents.. *Kidney360*, **2020**, 1, 1060-1067	1.8	0
207	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. *American Journal of Kidney Diseases*, **2020**, 76, 842-850	7.4	2
206	Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 in the Coronary Artery Risk Development in Young Adults Study. *Journal of Renal Nutrition*, **2020**, 30, 509-517	3	3
205	Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases*, **2020**, 75, 235-244	7.4	18
204	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. *CKJ: Clinical Kidney Journal*, **2020**, 13, 75-84	4.5	12
203	A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 161-174	12.7	20
202	Pulmonary Hypertension Subtypes and Mortality in CKD. *American Journal of Kidney Diseases*, **2020**, 75, 713-724	7.4	12
201	Regulation and Effects of FGF23 in Chronic Kidney Disease. *Annual Review of Physiology*, **2020**, 82, 365-390	29.1	35
200	Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. *American Journal of Kidney Diseases*, **2020**, 75, 908-918	7.4	7
199	Association between patient race and staff resuscitation efforts after cardiac arrest in outpatient dialysis clinics: A study from the CARES surveillance group. *Resuscitation*, **2020**, 156, 42-50	4	2
198	Fibroblast Growth Factor-23 and a Vegetarian Diet. *Journal of Renal Nutrition*, **2020**, 30, 503-508	3	1
197	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. *Bone*, **2020**, 141, 115559	4.7	3
196	FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. *Nature Reviews Nephrology*, **2020**, 16, 7-19	14.9	93
195	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		
194	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		
193	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		
192	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		

191	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		
190	Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study **2020**, 15, e0226509		
189	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. *American Journal of Kidney Diseases*, **2019**, 74, 771-781	7.4	10
188	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. *Kidney International*, **2019**, 96, 1346-1358	9.9	29
187	FGFR4 does not contribute to progression of chronic kidney disease. *Scientific Reports*, **2019**, 9, 14023	4.9	8
186	Association of Fitness With Racial Differences in Chronic Kidney Disease. *American Journal of Preventive Medicine*, **2019**, 57, 68-76	6.1	0
185	Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. *Scientific Reports*, **2019**, 9, 8877	4.9	13
184	Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1096-1108	12.7	63
183	Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2267-2276	5.6	6
182	DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. *Bone Research*, **2019**, 7, 12	13.3	39
181	Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study. *American Journal of Nephrology*, **2019**, 49, 263-270	4.6	10
180	Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases*, **2019**, 74, 203-212	7.4	1
179	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. *American Journal of Kidney Diseases*, **2019**, 73, 806-814	7.4	40
178	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1495-1504	12.7	38
177	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. *American Journal of Nephrology*, **2019**, 50, 105-114	4.6	5
176	Does a rise in plasma erythropoietin after high-altitude exposure affect FGF23 in healthy volunteers on a normal or low-phosphorus diet?. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 1361-1367	4.5	3
175	Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. *Kidney International Reports*, **2019**, 4, 1598-1607	4.1	9
174	Vitamin D and Health Outcomes: Then Came the Randomized Clinical Trials. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1866-1868	27.4	15

173	Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study. *American Journal of Kidney Diseases*, **2019**, 73, 344-353	7.4	42
172	Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study. *Kidney International Reports*, **2019**, 4, 80-93	4.1	8
171	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. *American Journal of Hypertension*, **2019**, 32, 18-25	2.3	10
170	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. *Nephrology Dialysis Transplantation*, **2019**, 34, 339-346	4.3	19
169	Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 531-541	6.9	33
168	A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial. *Kidney International Reports*, **2018**, 3, 5-10	4.1	
167	Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. *Kidney International Reports*, **2018**, 3, 364-373	4.1	5
166	Genetic background influences cardiac phenotype in murine chronic kidney disease. *Nephrology Dialysis Transplantation*, **2018**, 33, 1129-1137	4.3	22
165	FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study. *Hypertension*, **2018**, 72, 70-76	8.5	23
164	Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos. *Bone*, **2018**, 114, 278-284	4.7	1
163	Urban foodscape trends: Disparities in healthy food access in Chicago, 2007-2014. *Health and Place*, **2018**, 52, 231-239	4.6	27
162	Randomized trial of intravenous iron-induced hypophosphatemia. *JCI Insight*, **2018**, 3,	9.9	80
161	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 579-590	12.7	88
160	Chicago supermarket data and food access analytics in census tract shapefiles for 2007-2014. *Data in Brief*, **2018**, 21, 2482-2488	1.2	4
159	Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study. *PLoS ONE*, **2018**, 13, e0206839	3.7	10
158	Statins at Dialysis Transition-Supportive but Not Sufficient. *JAMA Network Open*, **2018**, 1, e182411	10.4	1
157	Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 2583-2592	12.7	19
156	Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. *Kidney International Reports*, **2018**, 3, 1467-1472	4.1	9

155	Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes. *PLoS ONE*, **2018**, 13, e0203460	3.7	9
154	Metabolic Changes with Base-Loading in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 1244-1246	6.9	5
153	Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis. *Cytokine*, **2017**, 91, 124-127	4	9
152	Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1181-1189	6.9	33
151	Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2017**, 313, L16-L26	5.8	26
150	Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. *American Journal of Hypertension*, **2017**, 30, 822-829	2.3	6
149	FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. *Scientific Reports*, **2017**, 7, 1993	4.9	70
148	Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. *Journal of the American Heart Association*, **2017**, 6,	6	47
147	The Authors Reply. *Kidney International*, **2017**, 91, 1518-1519	9.9	
146	Acid Load and Phosphorus Homeostasis in CKD. *American Journal of Kidney Diseases*, **2017**, 70, 541-550	7.4	14
145	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. *JAMA Cardiology*, **2017**, 2, 635-643	16.2	154
144	Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes. *Kidney International*, **2017**, 91, 204-215	9.9	38
143	Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. *Kidney International*, **2017**, 91, 711-719	9.9	65
142	Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1877-1885	12.7	57
141	Genetic Variants Associated with Circulating Parathyroid Hormone. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1553-1565	12.7	37
140	Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry. *Journal of Bone and Mineral Metabolism*, **2017**, 35, 666-674	2.9	7
139	FGF23 and Nutritional Metabolism. *Annual Review of Nutrition*, **2017**, 37, 247-268	9.9	23
138	Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1795-1803	6.9	38

137	Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1461-1469	6.9	11
136	Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4648-4657	5.6	9
135	Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. *Nephrology Dialysis Transplantation*, **2017**, 32, 1566-1578	4.3	12
134	Asymptomatic Ventricular Arrhythmia and Clinical Outcomes in Chronic Kidney Disease: A Pilot Study. *CardioRenal Medicine*, **2016**, 7, 66-73	2.8	7
133	Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. *Kidney International*, **2016**, 90, 985-996	9.9	219
132	Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. *JAMA Cardiology*, **2016**, 1, 548-56	16.2	63
131	Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. *Kidney International*, **2016**, 89, 939-48	9.9	54
130	Genetic African Ancestry and Markers of Mineral Metabolism in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 653-62	6.9	11
129	Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. *Stroke*, **2016**, 47, 923-8	6.7	22
128	The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease. *Canadian Journal of Cardiology*, **2016**, 32, 369-77	3.8	25
127	Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. *Kidney International*, **2016**, 89, 135-46	9.9	279
126	Pruning the ricket thicket. *Journal of Clinical Investigation*, **2016**, 126, 473-6	15.9	1
125	Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. *American Journal of Kidney Diseases*, **2016**, 68, 545-553	7.4	18
124	Atrial Fibrillation and Risk of ESRD in Adults with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1189-96	6.9	50
123	Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 2246-53	5.6	15
122	Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 1673-9	5.6	13
121	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. *Transplantation*, **2016**, 100, 184-93	1.8	76
120	Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3779-3786	5.6	58

119	Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. *Journal of the American Heart Association*, **2015**, 4,	6	49
118	Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. *Nephrology Dialysis Transplantation*, **2015**, 30, 1534-41	4.3	9
117	Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry. *Nephrology Dialysis Transplantation*, **2015**, 30, 630-5	4.3	16
116	Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. *American Journal of Kidney Diseases*, **2015**, 66, 258-65	7.4	86
115	Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. *Cell Metabolism*, **2015**, 22, 1020-32	24.6	345
114	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 2128-35	6.9	24
113	Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2048-53	9.4	27
112	When there will never be a randomized controlled trial. *Kidney International*, **2015**, 88, 220-2	9.9	8
111	Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 1875-85	6.9	21
110	Food Access, Chronic Kidney Disease, and Hypertension in the U.S. *American Journal of Preventive Medicine*, **2015**, 49, 912-20	6.1	48
109	Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. *Circulation*, **2015**, 131, 254-62	16.7	78
108	High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 946-56	12.7	74
107	Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1290-302	12.7	187
106	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 2328-39	12.7	95
105	A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. *American Journal of Kidney Diseases*, **2015**, 65, 728-36	7.4	101
104	Fibroblast growth factor 23 and incident CKD in type 2 diabetes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 29-38	6.9	16
103	Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. *Nature Reviews Nephrology*, **2014**, 10, 268-78	14.9	128
102	Fibroblast growth factor-23 and cardiovascular events in CKD. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 349-60	12.7	306

101	Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). *Neurology*, **2014**, 82, 1706-6	6.9	49
100	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. *Rheumatology*, **2014**, 53, 1613-7	3.9	8
99	Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. *Nephrology Dialysis Transplantation*, **2014**, 29, 2028-35	4.3	72
98	Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. *Current Opinion in Nephrology and Hypertension*, **2014**, 23, 411-9	3.5	131
97	Disordered FGF23 and mineral metabolism in children with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 344-53	6.9	111
96	Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study. *Journal of Renal Nutrition*, **2014**, 24, 186-93	3	9
95	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. *Kidney International*, **2013**, 83, 789-91	9.9	16
94	Plasma FGF23 levels increase rapidly after acute kidney injury. *Kidney International*, **2013**, 84, 776-85	9.9	119
93	Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. *American Journal of Kidney Diseases*, **2013** , 62, 670-8	7.4	152
92	Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. *American Journal of Kidney Diseases*, **2013**, 61, 67-73	7.4	34
91	A physiologic-based approach to the evaluation of a patient with hyperphosphatemia. *American Journal of Kidney Diseases*, **2013**, 61, 330-6	7.4	5
90	Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, 12-20	3	19
89	Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. *American Journal of Kidney Diseases*, **2013**, 62, 457-73	7.4	60
88	Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 1009-18	6.9	104
87	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. *Kidney International*, **2013**, 83, 1159-68	9.9	251
86	FGF23 modifies the relationship between vitamin D and cardiac remodeling. *Circulation: Heart Failure*, **2013**, 6, 817-24	7.6	36
85	Mineral metabolites and CKD progression in African Americans. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 125-35	12.7	68
84	Phosphate Metabolism and Fibroblast Growth Factor 23 in Chronic Kidney Disease **2013**, 285-308		3

83	Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. *Clinical Endocrinology*, **2013**, 79, 491-8	3.4	55
82	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. *Journal of Bone and Mineral Research*, **2013**, 28, 1793-803	6.3	250
81	Phosphate: a novel cardiovascular risk factor. *European Heart Journal*, **2013**, 34, 1099-101	9.5	25
80	Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 820-8	6.9	40
79	Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. *JAMA - Journal of the American Medical Association*, **2012**, 308, 1898-905	27.4	131
78	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. *International Urology and Nephrology*, **2012**, 44, 1169-75	2.3	8
77	Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA). *Journal of Renal Nutrition*, **2012**, 22, 480-9	3	19
76	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. *Diabetes Research and Clinical Practice*, **2012**, 97, 71-6	7.4	62
75	Effects of phosphate binders in moderate CKD. *Journal of the American Society of Nephrology: JASN* , **2012**, 23, 1407-15	12.7	398
74	Update on fibroblast growth factor 23 in chronic kidney disease. *Kidney International*, **2012**, 82, 737-47	9.9	264
73	Fibroblast growth factor 23 and Inflammation in CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1155-62	6.9	191
72	Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. *Diabetes Care*, **2012**, 35, 994-1001	14.6	45
71	FGF-23 levels in patients with AKI and risk of adverse outcomes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1217-23	6.9	58
70	Expression of fgf23 and klotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio. *Nephrology Dialysis Transplantation*, **2012**, 27, 4314-22	4.3	22
69	Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. *Nephrology Dialysis Transplantation*, **2012**, 27, 3270-8	4.3	74
68	Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. *Clinical Chemistry*, **2012**, 58, 1342-51	5.5	109
67	(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 139-45	6.9	28
66	Klotho: FGF23 coreceptor and FGF23-regulating hormone. *Journal of Clinical Investigation*, **2012**, 122, 4336-9	15.9	13

65	Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. *Journal of Renal Nutrition*, **2011**, 21, 295-302	3	56
64	Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney International*, **2011**, 79, 1370-8	9.9	817
63	FGF23 induces left ventricular hypertrophy. *Journal of Clinical Investigation*, **2011**, 121, 4393-408	15.9	1351
62	Association of serum phosphorus level with anemia in kidney transplant recipients. *Transplantation*, **2011**, 91, 875-82	1.8	17
61	Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. *Pediatric Transplantation*, **2011**, 15, 37-46	1.8	18
60	Should activated vitamin D be used in patients with end-stage renal disease and low levels of parathyroid hormone?. *Seminars in Dialysis*, **2011**, 24, 428-30	2.5	2
59	Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes. *Cardiovascular Drugs and Therapy*, **2011**, 25, 215-22	3.9	3
58	Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey. *Journal of Renal Nutrition*, **2011**, 21, 140-8	3	30
57	Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 584-91	4.3	136
56	Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. *Nephrology Dialysis Transplantation*, **2011**, 26, 1258-65	4.3	32
55	Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2871-8	6.9	121
54	Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2688-95	6.9	59
53	Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. *JAMA - Journal of the American Medical Association*, **2011**, 305, 2432-9	27.4	741
52	Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 956-66	12.7	222
51	Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2612-9	6.9	38
50	Low socioeconomic status associates with higher serum phosphate irrespective of race. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1953-60	12.7	76
49	Forging forward with 10 burning questions on FGF23 in kidney disease. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1427-35	12.7	214
48	Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. *Nephrology Dialysis Transplantation*, **2010**, 25, 2368-75	4.3	11

47	Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. *Nephrology Dialysis Transplantation*, **2010**, 25, 1335-7	4.3	25
46	Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 578-85	5.6	178
45	Vitamin D deficiency and anemia in early chronic kidney disease. *Kidney International*, **2010**, 77, 715-20	9.9	88
44	Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2010**, 25, 3970-7	4.3	34
43	Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. *Diabetes*, **2010**, 59, 242-8	0.9	356
42	Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet, The*, **2010**, 376, 180-8	40	1183
41	Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2010**, 19, 335-42	3.5	25
40	Chronic kidney disease in patients with cognitive impairment: a marker of microvascular damage or an independent risk factor?. *Aging Health*, **2010**, 6, 423-427		
39	Diagnosis and management of mineral metabolism in CKD. *Journal of General Internal Medicine*, **2010**, 25, 710-6	4	13
38	FGF-23: More than a regulator of renal phosphate handling?. *Journal of Bone and Mineral Research*, **2010**, 25, 2091-7	6.3	120
37	Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. *Seminars in Dialysis*, **2010**, 23, 401-6	2.5	33
36	Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation*, **2009**, 119, 2545-52	16.7	645
35	Integrating research training into residency: tools of human investigation. *Academic Medicine*, **2009**, 84, 1295-300	3.9	16
34	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. *Kidney International*, **2009**, 76, 705-16	9.9	75
33	Plasma gelsolin and circulating actin correlate with hemodialysis mortality. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1140-8	12.7	71
32	Phosphorus binders and survival on hemodialysis. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 388-96	12.7	299
31	Klotho variants and chronic hemodialysis mortality. *Journal of Bone and Mineral Research*, **2009**, 24, 1847-55	6.3	45
30	Fibroblast growth factor 23 and the future of phosphorus management. *Current Opinion in Nephrology and Hypertension*, **2009**, 18, 463-8	3.5	36

29	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *New England Journal of Medicine*, **2008**, 359, 584-92	59.2	1320
28	N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. *Clinical Chemistry*, **2008**, 54, 1339-48	5.5	34
27	Active vitamin D and survival. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1442-3	12.7	7
26	Calciphylaxis from nonuremic causes: a systematic review. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 1139-43	6.9	257
25	Impact of activated vitamin D and race on survival among hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1379-88	12.7	145
24	Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 615-23	12.7	118
23	Vitamin D deficiency and risk of cardiovascular disease. *Circulation*, **2008**, 117, 503-11	16.7	1770
22	Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. *Hypertension*, **2007**, 49, 612-7	8.5	98
21	Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. *Journal of Steroid Biochemistry and Molecular Biology*, **2007**, 103, 487-90	5.1	37
20	Clinical problem-solving. Needle in a haystack. *New England Journal of Medicine*, **2006**, 354, 68-73	59.2	11
19	Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1115-25	12.7	687
18	Postpartum diabetes screening in women with a history of gestational diabetes. *Obstetrics and Gynecology*, **2005**, 106, 1297-303	4.9	108
17	Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. *American Journal of Obstetrics and Gynecology*, **2005**, 193, 16-22	6.4	105
16	Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. *Seminars in Dialysis*, **2005**, 18, 302-6	2.5	20
15	Early pregnancy insulin resistance and subsequent gestational diabetes mellitus. *Diabetes Care*, **2005**, 28, 1207-8	14.6	30
14	Case records of the Massachusetts General Hospital. Case 28-2005. A 42-year-old man with weight loss, weakness, and a rash. *New England Journal of Medicine*, **2005**, 353, 1148-57	59.2	5
13	Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2205-15	12.7	679
12	Differential risk of hypertensive disorders of pregnancy among Hispanic women. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1330-8	12.7	46

11	Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. *Hypertension*, **2004**, 43, 988-92	8.5	84
10	Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 6239-43	5.6	165
9	First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 770-5	5.6	353
8	First-trimester C-reactive protein and subsequent gestational diabetes. *Diabetes Care*, **2003**, 26, 819-24	14.6	178
7	First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. *American Journal of Obstetrics and Gynecology*, **2003**, 189, 171-6	6.4	79
6	Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *New England Journal of Medicine*, **2003**, 349, 446-56	59.2	769
5	Patients with Fabry disease on dialysis in the United States. *Kidney International*, **2002**, 61, 249-55	9.9	134
4	Clinical research career development: the individual perspective. *Academic Medicine*, **2002**, 77, 1084-8	3.9	25
3	First trimester insulin resistance and subsequent preeclampsia: a prospective study. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1563-8	5.6	169
2	Insulin resistance but not inflammation is associated with gestational hypertension. *Hypertension*, **2002**, 40, 886-91	8.5	40
1	Obesity and Preeclampsia. *Obstetrics and Gynecology*, **2001**, 98, 757-762	4.9	82